Nasus Pharma Ltd. (NSRX)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 20-FLatest | FY-2025 | — |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | — |
|
| Statements | ||
| Consolidated Balance Sheets | — |
|
| Consolidated Balance Sheets (P) | — |
|
| Consolidated Statements of Operations | — |
|
| Consolidated Statements of Operations (P) | — |
|
| Consolidated Statements of Changes In Shareholders' Equity (deficit) | — |
|
| Consolidated Statements of Cash Flows | — |
|
| Consolidated Statements of Cash Flows (P) | — |
|
| Notes | ||
| Contingent Liabilities and Commitments | — |
|
| Convertible Securities | — |
|
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Discontinued Operations | — |
|
| Fair Value Measurements | — |
|
| Insider Trading Policies and Procedures | — |
|
| Lease | — |
|
| Net Loss Per Share Attributable To Shareholder | — |
|
| Organization and Nature of The Business | — |
|
| Pay Vs Performance Disclosure | — |
|
| Prepaid Expenses and Other Current Assets and Accrued Expense and Other Current Liabilities | — |
|
| Related Parties | — |
|
| Segment Reporting | — |
|
| Share-based Payments | — |
|
| Shareholders Equity (deficit) | — |
|
| Short-term Debt From Shareholders | — |
|
| Significant Accounting Policies | — |
|
| Subsequent Events | — |
|
| Taxes On Income | — |
|